AstraZeneca’s Imfinzi delivers positive results in management of lung cancer
Interim results from a clinical trial involving AstraZeneca’s Imfinzi (durvalumab) has delivered better efficacy when combined with neoadjuvant chemotherapy rather than chemotherapy alone. This has been observed in management of resectable non-small cell lung cancer. The phase 3 study, coded…
